Figure 4.

Association of gene mutations with ICI outcomes and biomarker status. UpSet plot showing gene mutations that were significantly (p<0.05) enriched in patient groups or associated with PFS or OS in multivariate analysis of all WES patients or univariate analysis within 2L-PD-L1 TPS-high and -low subgroups. Each column represents a set of gene mutations that was significant in a specific combination of one-or-more survival or enrichment analyses. Color represents whether a mutation was associated with improved PFS, OS, or disease control (green); reduced PFS, OS, no disease control (red); or only associated with biomarkers or metastases in more than one organ system (multiorgan mets) (blue). Right barplot shows the total number of significant gene mutations (hits) in each analysis. For all biomarker groups (PD-L1, AXL Hscore, AXL IC, and TMB), there were no enriched gene mutations in the opposing group (e.g. PD-L1 TPS-low).